Although our previous research showed that KRAS mutations are prevalent as subpopulations in lung adenocarcinomas [29], we observed outgrowth of PIK3CA H1047R more frequently than KRAS mutations, which is consistent with analyses of resistance-associated driver mutations collected in the clinical setting [39]. This evidence concerns the gene KRAS and lung adenocarcinoma.